AML study reports high response rates with combination targeted therapy
Initial findings from a multi-national open-label phase Ib study of inhibitory drug therapy for relapsed or refractory acute myeloid leukemia (AML) have demonstrated a complete response in up to 50 percent patients say researchers at The University of Texas MD Anderson Cancer Center .
The patients, age 60 years or older, received therapy with venetoclax in combination with cobimetinib or idasanutlin. The clinical trial followed...
Phase 2 CAR-T study reports significant remission rates at 15-month follow up
A study involving the recently approved CD19-targeting chimeric antigen receptor (CAR) T cell therapy shows that 42 percent of patients with...
Novel regulation of gene expression in brain tumors identified
Study results revealed previously unknown interplay between two key enzymes and a novel understanding of how brain cancer tumors form and...
MD Anderson to present key drug study findings for multiple blood cancers at ASH annual meeting
Researchers at The University of Texas MD Anderson Cancer Center will present their latest findings involving drug treatments for blood cancers at the American Society of Hematology’s (ASH) Annual Meeting & Exposition Dec. 8-12 in Atlanta.
“There can be no doubt that we are in an exciting new era of treatment of blood cancers as evidenced by key presentations by MD Anderson researchers at this year’s ASH meeting,” said Patrick...
Peter WT Pisters, M.D., begins tenure as president of MD Anderson
The University of Texas MD Anderson Cancer Center today welcomes Peter WT Pisters, M.D., as its fifth full-time president in the institution...
Six researchers from MD Anderson elected as AAAS Fellows
In recognition of their contributions to basic, translational, and clinical research, six faculty members from The University of Texas...
Seres Therapeutics, MD Anderson Cancer Center, and the Parker Institute for Cancer Immunotherapy Announce a Collaboration to Support the Investigation of Microbiome Therapeutics for Immuno-Oncology
Seres Therapeutics, Inc., The University of Texas MD Anderson Cancer Center and the Parker Institute for Cancer Immunotherapy today...
Thousands support MD Anderson’s Boot Walk to End Cancer®
Thousands of patients, family members, volunteers, friends and employees of The University of Texas MD Anderson Cancer Center participated...
Seven leaders join MD Anderson Cancer Center Board of Visitors
The University of Texas MD Anderson Cancer Center Board of Visitors (BOV) welcomed seven new members at its annual meeting today. They include...
Circulating tumor cells associated with relapse in late-stage melanoma patients
A study revealing a connection between circulating tumor cells (CTCs) and relapse in stage IV melanoma patients points to liquid biopsy as...
Dream Team aims to intercept pancreatic cancer before it flourishes
Deeply entrenched and mature by the time it’s found, pancreatic cancer is one of the hardest to defeat. A Dream Team assembled by Stand...
V. Craig Jordan, Ph.D., elected to the National Academy of Medicine
V. Craig Jordan, Ph.D., professor of Breast Medical Oncology, has been elected to the National Academy of Medicine for his discovery of selective...
MD Anderson team selected for national push to expand immunotherapy
A major national effort to expand the reach of cancer immunotherapy to benefit more patients will draw upon the expertise of a team of researchers...
MD Anderson expert to lead free Austin panel on Alzheimer’s disease
The University of Texas MD Anderson Cancer Center and Belmont Village Senior Living will present a free panel discussion in Austin exploring...
MD Anderson and BridgeBio Pharma launch Navire Pharma to develop targeted therapy for patients with difficult-to-treat cancer
The University of Texas MD Anderson Cancer Center and BridgeBio Pharma today announced the launch of Navire Pharma, a biopharmaceutical company...
MD Anderson Cancer Center and Pfizer Oncology announce clinical collaboration
The University of Texas MD Anderson Cancer Center and Pfizer Inc. today announced that they have entered into a clinical collaboration...
Study shows diet and exercise improve treatment outcomes for obese pediatric cancer patients
Diet and exercise may improve treatment outcomes in pediatric cancer patients, according to a study at The University of Texas MD Anderson...
Tibetan yoga practice may improve sleep quality for breast cancer patients receiving chemotherapy
Participating in twice-weekly practice of Tibetan yoga may reduce sleep disturbances and improve sleep quality in breast cancer patients receiving...
Following Hurricane Harvey, MD Anderson maintains exceptional patient care, supports staff
Through dedicated teamwork, strategic planning and the support of its internal and external communities, The University of Texas MD Anderson...
Making Cancer History®: Free seminar returns to Atlanta
The University of Texas MD Anderson Cancer Center brings its signature Making Cancer History® Seminar to Atlanta for the third time, 8:30-...
MD Anderson’s Keeling Center Open House set for April 21
The University of Texas MD Anderson Cancer Center’s Michale E. Keeling Center for Comparative Medicine and Research will open its doors to...
Obituary for Charles Aubrey LeMaistre, M.D.
Charles Aubrey LeMaistre, M.D.
1924-2017
Charles Aubrey “Mickey” LeMaistre, M.D., beloved physician, father, trusted friend...
A Conversation With a Living Legend® honors international architect Santiago Calatrava
The 28th annual A Conversation With a Living Legend® in Dallas, Sept. 14 at the Hilton Anatole, honors architect, artist and engineer Santiago...
MD Anderson ranked top cancer hospital in annual survey
The University of Texas MD Anderson Cancer Center again has ranked No. 1 for cancer care by U.S. News & World Report’s annual “Best Hospitals...
Concurrent chemotherapy, proton therapy improves survival in patients with advanced lung cancer
For patients with advanced, inoperable stage 3 lung cancer, concurrent chemotherapy and the specialized radiation treatment, proton therapy...
Genetically enhanced, cord-blood derived immune cells strike B-cell cancers
Immune cells with a general knack for recognizing and killing many types of infected or abnormal cells also can be engineered to hunt down...
Tumor-targeting drug shows potential for treating bone cancer patients
The treatment of osteosarcoma, the most common tumor of bone, is challenging. A study led by The University of Texas MD Anderson Cancer Center...
MD Anderson announces new leadership structure
The University of Texas MD Anderson Cancer Center today announced a new leadership structure designed to enhance teamwork and collaborative...
MD Anderson UTHealth Graduate School receives $10.5 million gift
Just as he has changed the lives of people suffering from a devastating genetic disease, molecular endocrinologist John J. Kopchick, Ph.D....
Making Cancer History® Seminar returns to Aspen
The University of Texas MD Anderson Cancer Center plans its 19th annual Making Cancer History® seminar in Aspen, free and open to the public...
MD Anderson and Convergent R.N.R. Ltd. establish alliance to further develop new radiation technology with potentially fewer side effects
The University of Texas MD Anderson Cancer Center and Convergent R.N.R. Ltd. (CRnR) today announced a collaboration to further develop new...
Innovative therapy strategy for pancreatic cancer uses engineered exosomes targeting mutated KRAS gene
Genetic manipulation of exosomes, virus-sized particles released by all cells, may offer a new therapeutic approach to treating pancreatic...
MD Anderson and Hitachi to collaborate in research for treatment of oropharyngeal cancer of the head and neck
The University of Texas MD Anderson Cancer Center and Hitachi Healthcare Americas Corporation, have today announced that they have entered...
Higher gut bacteria diversity tied to slower metastatic melanoma progression
The blend of bacteria in the digestive tract of metastatic melanoma patients is associated with disease progression or delay in patients treated...
Two combination therapies shrink melanoma brain metastases in more than half of patients
High response rates to a pair of combination therapies point to potentially new options for a group of metastatic melanoma patients who have...
Image-guided biopsies accurately identify breast cancer patients who achieve pathologic complete response following neoadjuvant therapy
In a clinical feasibility trial conducted at The University of Texas MD Anderson Cancer Center, image-guided biopsies identified select breast...
Study provides better understanding of how brain tumors ‘feed’
All cancer tumors have one thing in common – they must feed themselves to grow and spread, a difficult feat since they are usually in a tumor...
San Diego Zoo Kids brings world of animals to MD Anderson pediatric cancer patients
The University of Texas MD Anderson Children’s Cancer Hospital today debuted San Diego Zoo Kids, a new television channel for patients and...
Ellis Island Medal of Honor Presented to Ronald DePinho, M.D.
Ronald DePinho, M.D., professor of biology and former president, The University of Texas MD Anderson Cancer Center, is among the recipients...
MD Anderson convenes global network of cancer-fighting institutions
More than 800 cancer doctors, nurses and scientists from all over the world will gather at The University of Texas MD Anderson Cancer Center...
MD Anderson names Ben Melson new chief financial officer
The University of Texas MD Anderson Cancer Center has announced that Ben Melson will become the institution’s senior vice president and chief...
MD Anderson genetics expert Guillermina Lozano elected to National Academy of Sciences
Guillermina Lozano, Ph.D., chair of Genetics at The University of Texas MD Anderson Cancer Center, has been elected to the prestigious National...
Jim Allison named one of TIME’s 100 most influential people
The University of Texas MD Anderson Cancer Center Chair of Immunology Jim Allison, Ph.D., whose pivotal insight to attack cancer by treating...
Making Cancer History®: Free seminar returns to Midland
The University of Texas MD Anderson Cancer Center brings its signature Making Cancer History® Seminar to Midland, for the second time, 11:...
MD Anderson, Oncora Medical team up to fight cancer with precision medicine alliance
Oncora Medical, a precision radiation oncology software company, and The University of Texas MD Anderson Cancer Center, today announced a...
Stand Up to Cancer innovation grant funds MD Anderson microbiome study
An Innovative Research Grant from Stand Up to Cancer will help a University of Texas MD Anderson Cancer Center physician scientist and her...
Immunologic changes point to potential for clinical investigation of combination immunotherapy for deadly kidney cancer
Immunologic changes observed in an early study of patients with metastatic renal cell carcinoma (MRCC) raised the possibility for a larger...
Minority colorectal cancer patients report higher burden of poor quality-of-life than whites
A study of racial disparities in health-related quality of life of colorectal cancer patients revealed among several findings, that Hispanics...
Study provides path for new immunotherapy approaches to prostate cancer
Prostate cancer, notoriously resistant to immunotherapy due to its immunologically cool nature, triggers two pathways to chill an immune attack...
Jerry Jeff Walker to headline April 29 Polo on the Prairie in West Texas
The 31st annual Polo on the Prairie, a U.S. Polo Association-sanctioned event benefiting cancer research and patient care programs at The...
MD Anderson expert to lead Dallas panels on Alzheimer’s disease
The University of Texas MD Anderson Cancer Center brings Jim Ray, Ph.D., head of Neuroscience, to Dallas on Thursday, April 20, to lead two...
Marshall E. Hicks named interim president of UT MD Anderson Cancer Center
University of Texas System Chancellor William H. McRaven announced today the appointment of Marshall E. Hicks, M.D., as interim president...
Advanced form of proton therapy shows promise for treating lung cancer recurrence
An advanced form of image-guided radiation therapy, known as intensity modulated proton therapy (IMPT), has shown early promise for the treatment...
Change in Leadership at MD Anderson
Ronald A. DePinho M.D., president of The University of Texas MD Anderson Cancer Center, has submitted a letter to Chancellor William H. McRaven...
Statement from The University of Texas System Chancellor William H. McRaven
When Dr. Ron DePinho was named president of The University of Texas MD Anderson Cancer Center by the Board of Regents in 2011, ...
Functional brain training alleviates chemotherapy-induced peripheral nerve damage in cancer survivors
A type of functional brain training known as neurofeedback shows promise in reducing symptoms of chemotherapy-induced nerve damage, or neuropathy...
MD Anderson to provide skin cancer screenings, cancer prevention education at Shell Houston Open
Cancer prevention specialists from The University of Texas MD Anderson Cancer Center will provide skin cancer screenings free to the public...
Absent tumor-suppressors allow melanoma to thwart immunotherapy
It’s what’s missing in the tumor genome, not what’s mutated, that thwarts treatment of metastatic melanoma with immune checkpoint...
Two migration proteins boost predictive value of pancreatic cancer biomarker
Adding two blood-borne proteins associated with cancer cell migration increases the predictive ability of the current biomarker for pancreatic...
Study reveals PGK1 enzyme as therapeutic target for deadliest brain cancer
Discovery of a dual role played by the enzyme phosphoglycerate kinase 1 (PGK1) may indicate a new therapeutic target for glioblastoma, an...
Lung cancer cells susceptible to inhibitor treatment via newly discovered pathway
Next-generation cyclin dependent kinase 2/9 (CDK2/9) inhibitors offer a novel way to treat lung cancer with minimal toxic side effects on...
Gut bacteria associated with cancer immunotherapy response in melanoma
Melanoma patients’ response to a major form of immunotherapy is associated with the diversity and makeup of trillions of potential allies...
Hormonal maintenance therapy may improve survival in women with chemo-resistant rare ovarian or peritoneum cancer
For women with a rare subtype of epithelial ovarian or peritoneum cancer, known as low-grade serous carcinoma (LGSC), hormone maintenance...
More patients with early-stage breast cancer may be able to avoid chemotherapy in the future
Women with early-stage breast cancer who had an intermediate risk recurrence score (RS) from a 21-gene expression assay had similar outcomes...
Scientists identify aggressive pancreatic cancer cells and their vulnerability
Researchers have identified a gatekeeper protein that prevents pancreatic cancer cells from transitioning into a particularly aggressive cell...
Recommendation for the further treatment of Chinese Nobel Prize Laureate Liu Xiaobo
Joint Statement from Dr. Joseph M. Herman, Clinical Research Director, Department of Radiation Oncology, The University of Texas MD Anderson...